Ariana Pharma
Created in 2003
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
2,827Activities
Technologies
Entity types
Location
60 Av. de la Grande Armée, 75017 Paris, France
Paris
France
Employees
Scale: 11-50
Estimated: 38
SIREN
449727205Engaged corporates
6
0 3Added in Motherbase
3 years, 6 months ago
biotech Value proposition
The leading xAI-driven drug development company
Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Ariana helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Ariana has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012.
Patient Stratification, Responder Analysis, Multi-objective lead optimization, Biomarker Development, Multiplex Biomarkers, Drug Safety, Drug Kit Optimization, and Personalized MedicineOriginal language
The leading xAI-driven drug development company
Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Ariana helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Ariana has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012.
Home - Ariana Pharma
Artificial Intelligence and Precision Medicine design leading to accelerated drug development and expedited regulatory approval
https://www.arianapharma.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Genopole Biotechnology, Biotechnology Research | Genopole Biotechnology, Biotechnology Research | Other 5 Jul 2024 | | |
 Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Other 5 Jul 2024 | | |
 CCI Paris IdF Chamber of commerce, Government Administration | CCI Paris IdF Chamber of commerce, Government Administration | Other 5 Jul 2024 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 5 Jul 2024 | | |
 STATION F Startup accelerator & VC, Software Development | STATION F Startup accelerator & VC, Software Development | Other 20 Nov 2022 | | |
 Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Other 24 Apr 2024 | | |